Search

Ipsen SA.

Uždarymo kaina

SektoriusFinansų sektorius

164.6 -0.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

164.3

Max

165.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

294M

403M

Pardavimai

334M

2.2B

P/E

Sektoriaus vid.

26.392

21.623

Dividendų pajamingumas

0.98

Pelno marža

18.405

Darbuotojai

5,535

EBITDA

556M

1B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+7.77% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

0.98%

4.44%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

349M

13B

Ankstesnė atidarymo kaina

164.66

Ankstesnė uždarymo kaina

164.6

Naujienos nuotaikos

By Acuity

29%

71%

79 / 436 reitingas Finance

Ipsen SA. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-05 00:05; UTC

News

Illumina Inc will join the S&P 500 on September 21, 2026. Shares are advancing in after-market hours following the announcement.

2026-09-05 00:05; UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

2026-09-05 00:01; UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

2026-09-05 00:01; UTC

Social Media
News

NIO shares are higher in after-market hours following a 69.1% revenue increase to approximately $4.74 billion and improved vehicle deliveries.

2026-09-05 00:01; UTC

News

Bloom Energy Corp will join the S&P 500 on September 21, 2026, boosting investor visibility. Shares are trading higher in after-market hours.

2026-09-05 00:01; UTC

News

Shares lower in after-market trading; Roth Capital targets $48.00.

2026-09-05 00:00; UTC

News

Campbell's Co shares increased in after-market trading following workforce cuts and price hikes aimed at improving profitability.

2026-09-05 00:00; UTC

News

DocuSign Inc reported stronger-than-expected second-quarter results but is trading lower in after-market hours, reflecting valuation concerns amid rising Treasury yields.

2026-09-04 23:40; UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

2026-09-04 23:35; UTC

News

AAP shares lower in after-market hours on analyst rating updates.

2026-09-04 23:27; UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

2026-09-04 23:20; UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

2026-09-04 23:10; UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

2026-09-04 23:05; UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

2026-09-04 23:02; UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

2026-09-04 23:02; UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

2026-09-04 23:02; UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

2026-09-04 23:00; UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

2026-09-04 23:00; UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

2026-09-04 23:00; UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

2026-09-04 22:51; UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

2026-09-04 20:08; UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

2026-09-04 20:08; UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

2026-09-04 20:08; UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

2026-09-04 20:08; UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

2026-09-04 20:08; UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

2026-09-04 20:08; UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

2026-09-04 20:08; UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

2026-09-04 20:08; UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

2026-09-04 20:08; UTC

News
Correlated Moves
Social Media

Advanced Micro Devices is rising as AI demand boosts projections for its EPYC CPUs, aided by partnerships like Microsoft’s Project Zenith.

Akcijų palyginimas

Kainos pokytis

Ipsen SA. Prognozė

Kainos tikslas

By TipRanks

7.77% į viršų

12 mėnesių prognozė

Vidutinis 177.5 EUR  7.77%

Aukščiausias 235 EUR

Žemiausias 135 EUR

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ipsen SA. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

3

Laikyti

1

Parduoti

Rinkos nuotaikos

By Acuity

79 / 436 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat